Oramed Pharmaceuticals Completes Strategic Pivot, Divests Oratech and Invests $9M in Lifeward

summarizeSummary

Oramed Pharmaceuticals has finalized its strategic shift by completing the disposition of its Oratech subsidiary to Lifeward Ltd. and simultaneously investing $9 million in Lifeward's convertible notes, receiving a significant equity stake and future revenue share.

check_boxKey Events

• Oratech Disposition Finalized

  Oramed completed the sale of its wholly-owned subsidiary, Oratech Pharma, Inc., to Lifeward Ltd., as previously agreed on January 12, 2026.

• Significant Equity Stake in Lifeward

  In consideration for Oratech, Oramed received 1,250,363 Lifeward Ordinary Shares, 1,006,113 Pre-Funded Warrants, and 1,296,296 Share Purchase Warrants in Lifeward.

• $9 Million Investment in Lifeward

  Oramed purchased $9,000,000 in Lifeward's senior secured convertible notes, along with warrants to purchase an additional 1,666,666 Lifeward Ordinary Shares, as part of a private placement.

• Future Revenue Sharing Agreement

  Oramed is entitled to 4% of Net Revenue from Lifeward's ReWalk Personal Exoskeleton products and related extended warranties, subject to certain caps and conditions.

auto_awesomeAnalysis

This 8-K confirms the execution of Oramed's previously announced strategic transformation from a biotech R&D company to an investment model. The completion of the Oratech disposition and the $9 million investment in Lifeward's convertible notes, along with the receipt of Lifeward shares, warrants, and a revenue-sharing agreement, fundamentally alters Oramed's asset base and future revenue streams. This move provides clarity on the company's new direction and its initial major investment, aligning with the strategic shift reported in the recent 10-K. Investors should monitor the performance of Lifeward and the realization of the revenue-sharing payments as key indicators of the success of this new strategy.